{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 376147382
| IUPAC_name = 3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-''d''][1,2,3,5]tetrazine-8-carboxamide
| image = Mitozolomide.svg
| width = 210

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 85622-95-3
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 71766
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = E3U7286V3W
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 435951
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 64805

<!--Chemical data-->
| C=7 | H=7 | Cl=1 | N=6 | O=2 
| molecular_weight = 242.622 g/mol
| smiles = NC(=O)c1ncn2C(=O)N(CCCl)\N=N/c12
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C7H7ClN6O2/c8-1-2-14-7(16)13-3-10-4(5(9)15)6(13)11-12-14/h3H,1-2H2,(H2,9,15)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = QXYYYPFGTSJXNS-UHFFFAOYSA-N
}}
'''Mitozolomide''' ([[International Nonproprietary Name|INN]]) is an [[antineoplastic]]. It is an [[imidazotetrazine]] derivative.

Development of mitozolomide was discontinued during [[clinical trial#Phase II|Phase II]] [[clinical trial]]s after it was found to cause severe and unpredictable [[myelosuppression|bone marrow suppression]].<ref>{{cite journal |vauthors=Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA |title=Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide |journal=Cancer Gene Ther |volume=7 |issue=2 |pages=233–9 |date=February 2000 |pmid=10770631 |url=http://www.nature.com/cgt/journal/v7/n2/pdf/7700120a.pdf |doi=10.1038/sj.cgt.7700120}}</ref> [[Temozolomide]], which has been in clinical use since 1999, is a less toxic [[analog (chemistry)|analogue]] of mitozolomide.<ref>{{cite journal  |vauthors=Newlands ES, Blackledge GR, Slack JA, etal |title=Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) |journal=Br J Cancer |volume=65 |issue=2 |pages=287–91 |date=February 1992 |pmid=1739631 |pmc=1977719 |doi=10.1038/bjc.1992.57}}</ref>

==References==
<references/>

{{Chemotherapeutic agents}}

[[Category:Abandoned drugs]]
[[Category:Imidazotetrazines]]
[[Category:Carboxamides]]
[[Category:Organochlorides]]

{{antineoplastic-drug-stub}}